Advocating for Australia’s life sciences. The sector solving the world’s most complex health problems and powering Australia’s economic growth.
HAwdlawj;dawhldaw
awdwadaw
awdaw
We deliver a commercialisation advisory service for Australian biotechnology and medical technology companies, drawing on 40 years of our industry expertise and networks.
AusBiotech’s IGP program provides expert mentoring, global market engagement with key regions including the United States, investment support, and targetted learning across regulatory, intellectual property and commercial strategy.
In 2025, we supported 32 biotechnology and medical technology companies
In 2025, we facilitated over 50 individual company pitch sessions
In 2026, we are supporting 43 companies through the IGP
Building sector capability
Access to expert 1:1 mentoring across critical areas from IP, regulatory to commercial strategy, as well as targeted workshops that build capability and accelerate commercialisation readiness.
Creating connections
Unlocking access to AusBiotech’s 3,500-member community, global leaders, and curated networking opportunities, including direct engagement with investors to support meaningful partnerships and growth.
Access to capital
Access to financial modelling and valuation, combined with investor readiness coaching and tailored pitch development, equipping innovators with the tools and confidence to secure investment.
“The AusBiotech IGP has been emmensly helpful for us. Not only preparing us, and getting us investment ready. But also connecting us with experts in the field, and also investors in the field who are interested in technologies such as ours and who can support us in our next stage of growth". Co-Founder and CEO Dr Dr Christoph Meinert, GAICD
Meet Gelomics →